26 completed, 5 terminated, 5 withdrawn, 4 recruiting. 12 Phase 2, 9 Phase 3, 7 Phase 4, 5 Not applicable, 1 Phase 1.
Follow Enterocolitis, Pseudomembranous: new trials by email Literature Review of Enterocolitis, Pseudomembranous trials Research Report on Enterocolitis, Pseudomembranous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Vancomycin Taper to Prevent Recurrent Clostridioides Difficile Fidaxomicin, Vancomycin capsule - Clostridia Difficile Colitis | Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 500 | 2026-04-24 | 2026-09-23 |
| Effect of Antibiotics on Enteric Neurons and Glia Amoxicillin Oral Capsule - Antibiotic Enterocolitis | Phase 4 | Completed | Rockefeller University | 10 | 2023-06-23 | 2026-03-12 |
| A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection RBX2660 - Clostridium Difficile Infection Recurrence | Phase 3 | Completed | Ferring Pharmaceuticals | 41 | 2023-04-21 | 2026-04-24 |
| REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs Dysbiosis, Clostridium Difficile | Active not recruiting | University of Pennsylvania | 200 | 2022-05-30 | 2026-10-09 | |
| Bezlotoxumab Versus FMT for Multiple Recurrent CDI Bezlotoxumab, Fecal Microbiota Transplantation (FMT), Vancomycin oral - Clostridium Infections, Clostridioides Difficile | Phase 4 | Withdrawn | Leiden University Medical Center | 2022-01-01 | 2023-03-28 | |
| Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) Alanyl-glutamine - Clostridioides Difficile Infection, Clostridium Difficile Infection | Phase 2 | Recruiting | University of Virginia | 260 | 2021-06-01 | 2024-10-26 |
| Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery. Bezlotoxumab, Normal Saline - Clostridia Difficile Colitis, Clostridium; Sepsis | Phase 4 | Terminated | Ohio State University | 5 | 2019-08-19 | 2026-06-18 |
| Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) RBX2660 - Clostridium Difficile Infection, Infection | Phase 3 | Completed | Rebiotix Inc. | 793 | 2019-07-30 | 2024-08-07 |
| Safety and Efficacy of Fecal Microbiota Transplantation Fecal Microbiota Transplantation - Crohn Disease, Ulcerative Colitis | Not applicable | Recruiting | Chinese University of Hong Kong | 450 | 2019-07-15 | 2024-08-22 |
| FQ Restriction for the Prevention of CDI fluoroquinolone preprescription authorization, Control - Clostridium Difficile, Clostridium Difficile Infection | Completed | University of Wisconsin, Madison | 5871 | 2019-05-01 | 2025-01-31 | |
| Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection Lyophilized fecal microbiota transplant, Lyophilized sterile fecal filtrate - Clostridia Difficile Colitis, Clostridium Difficile Diarrhea | Phase 2 | Completed | University of Alberta | 138 | 2019-03-21 | 2024-06-04 |
| Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection Vancomycin, Placebo - Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection | Phase 2 | Completed | University of Wisconsin, Madison | 79 | 2018-05-21 | 2025-05-25 |
| Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3) RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence) - Clostridium Difficile Infection (CDI) | Phase 3 | Completed | Rebiotix Inc. | 320 | 2017-07-31 | 2024-07-10 |
| Antimicrobial Stewardship Program for Clostridium Difficile Infection. Systematic evaluation by an ID expert. - Clostridium Difficile, Enterocolitis, Pseudomembranous | Completed | José María Aguado García, MD, PhD | 403 | 2017-02-15 | 2022-04-01 | |
| EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota Transplant fecal microbiota transplant - C.Difficile Colitis | Not applicable | Withdrawn | Milton S. Hershey Medical Center | 2016-09-15 | 2017-11-27 | |
| Stool Transplants to Treat Refractory Clostridium Difficile Colitis fecal microbiota - Clostridium Difficile Colitis | Phase 2 | Recruiting | Duke University | 77 | 2016-04-01 | 2026-08-27 |
| Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection Single-infusion FMT, Vancomycin (before randomization), multiple-infusion FMT - Clostridium Difficile, Pseudomembranous Colitis | Phase 2 | Completed | Catholic University of the Sacred Heart | 58 | 2016-03-01 | 2018-02-09 |
| Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile Cultured human intestinal microbiota, Vancomycin, Metronidazole - Clostridium Difficile | Phase 2 | Completed | Per Hellström | 60 | 2014-10-01 | 2019-01-09 |
| Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection FMT, placebo - Clostridium Difficile Colitis | Phase 2 | Completed | MemorialCare Health System | 9 | 2013-10-01 | 2016-09-01 |
Showing 20 of 43. Sign in to see all of them.
Clostridium Infections (10) · Diarrhea (7) · Dysentery (3) · Enterocolitis (3) · Colitis (2) · Colitis, Ulcerative (2) · Crohn Disease (2) · Graft vs Host Disease (2) · Multiple Sclerosis (2) · Alcoholism (1) · Alopecia (1) · Arthritis, Psoriatic (1) · Autistic Disorder (1) · Bacteremia (1)
Bacterial Infections and Mycoses (43) · Bacterial Infections (42) · Digestive System Diseases (42) · Gastroenteritis (42) · Gastrointestinal Diseases (42) · Gram-Positive Bacterial Infections (42) · Infections (42) · Intestinal Diseases (42) · Enterocolitis (40) · Clostridium Infections (33) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (9) · Pathologic Processes (8) · Signs and Symptoms, Digestive (8) · Colonic Diseases (3)
Vancomycin (6) · Fecal Microbiota Transplantation (5) · Metronidazole (3) · Saline Solution (3) · bezlotoxumab (2) · Adjuvants, Pharmaceutic (1) · Amoxicillin (1) · Enteral Nutrition (1) · Fidaxomicin (1) · Fluoridation (1) · Glutamine (1) · LFF571 (1) · Lacteol (1) · Oxygen (1) · Pantoprazole (1)
Genzyme, a Sanofi Company (5) · Michael E. DeBakey VA Medical Center (5) · Corewell Health East (2) · Rebiotix Inc. (2) · University of Wisconsin, Madison (2) · Ascension Health (1) · Beth Israel Medical Center (1) · Catholic University of the Sacred Heart (1) · Chinese University of Hong Kong (1) · Daniel M. Musher MD (1) · Duke University (1) · Ferring Pharmaceuticals (1) · Jay C. Buckey Jr. (1) · José María Aguado García, MD, PhD (1) · Leiden University Medical Center (1)
United States (30) · Canada (9) · Puerto Rico (2) · Spain (2) · Sweden (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hong Kong (1) · Ireland (1)
Daniel M Musher, M.D. (6) · Nasia Safdar, MD PhD (2) · Teena Chopra, M.D., M.P.H. (2) · Begum Aydin, PhD (1) · Christine H Lee, MD (1) · David S Seres, MD (1) · Dina Kao, MD (1) · Emily McDonald, MD MSc (1) · Gary M Cox, MD (1) · J van Prehn (1) · Jay Buckey (1)
PMID 42286373, PMID 24799326, PMID 41245385, PMID 10440607, PMID 11171619, PMID 21871249, PMID 23323867, PMID 25534724, PMID 25534727, PMID 27013431, PMID 28584140, PMID 29851107, PMID 31537446, PMID 34187821, PMID 36287379, PMID 37474181, PMID 37564743, PMID 38236515, PMID 39172632, PMID 39180326, PMID 40177588, PMID 40321366, PMID 40552763, PMID 40601321, PMID 40672762, PMID 40784972, PMID 40997843, PMID 41115624, PMID 41230019, PMID 41647268, PMID 41653256, PMID 42840322, PMID 9712236
K23AI163351 (1)